These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18941511)

  • 1. Development of a single vector system that enhances trans-splicing of SMN2 transcripts.
    Coady TH; Baughan TD; Shababi M; Passini MA; Lorson CL
    PLoS One; 2008; 3(10):e3468. PubMed ID: 18941511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
    Shababi M; Glascock J; Lorson CL
    Hum Gene Ther; 2011 Feb; 22(2):135-44. PubMed ID: 20804424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing.
    Coady TH; Shababi M; Tullis GE; Lorson CL
    Mol Ther; 2007 Aug; 15(8):1471-8. PubMed ID: 17551501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy.
    Coady TH; Lorson CL
    J Neurosci; 2010 Jan; 30(1):126-30. PubMed ID: 20053895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of SMN trans-splicing through the analysis of SMN introns.
    Shababi M; Lorson CL
    J Mol Neurosci; 2012 Mar; 46(3):459-69. PubMed ID: 21826391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMN deficiency alters Nrxn2 expression and splicing in zebrafish and mouse models of spinal muscular atrophy.
    See K; Yadav P; Giegerich M; Cheong PS; Graf M; Vyas H; Lee SG; Mathavan S; Fischer U; Sendtner M; Winkler C
    Hum Mol Genet; 2014 Apr; 23(7):1754-70. PubMed ID: 24218366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector.
    Baughan T; Shababi M; Coady TH; Dickson AM; Tullis GE; Lorson CL
    Mol Ther; 2006 Jul; 14(1):54-62. PubMed ID: 16580882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
    Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy.
    Naryshkin NA; Weetall M; Dakka A; Narasimhan J; Zhao X; Feng Z; Ling KK; Karp GM; Qi H; Woll MG; Chen G; Zhang N; Gabbeta V; Vazirani P; Bhattacharyya A; Furia B; Risher N; Sheedy J; Kong R; Ma J; Turpoff A; Lee CS; Zhang X; Moon YC; Trifillis P; Welch EM; Colacino JM; Babiak J; Almstead NG; Peltz SW; Eng LA; Chen KS; Mull JL; Lynes MS; Rubin LL; Fontoura P; Santarelli L; Haehnke D; McCarthy KD; Schmucki R; Ebeling M; Sivaramakrishnan M; Ko CP; Paushkin SV; Ratni H; Gerlach I; Ghosh A; Metzger F
    Science; 2014 Aug; 345(6197):688-93. PubMed ID: 25104390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
    Garbes L; Riessland M; Hölker I; Heller R; Hauke J; Tränkle C; Coras R; Blümcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2009 Oct; 18(19):3645-58. PubMed ID: 19584083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs.
    Madocsai C; Lim SR; Geib T; Lam BJ; Hertel KJ
    Mol Ther; 2005 Dec; 12(6):1013-22. PubMed ID: 16226920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
    Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J
    J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy.
    Pinard E; Green L; Reutlinger M; Weetall M; Naryshkin NA; Baird J; Chen KS; Paushkin SV; Metzger F; Ratni H
    J Med Chem; 2017 May; 60(10):4444-4457. PubMed ID: 28441483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurodevelopmental consequences of Smn depletion in a mouse model of spinal muscular atrophy.
    Liu H; Shafey D; Moores JN; Kothary R
    J Neurosci Res; 2010 Jan; 88(1):111-22. PubMed ID: 19642194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.
    Brichta L; Hofmann Y; Hahnen E; Siebzehnrubl FA; Raschke H; Blumcke I; Eyupoglu IY; Wirth B
    Hum Mol Genet; 2003 Oct; 12(19):2481-9. PubMed ID: 12915451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron.
    Singh NK; Singh NN; Androphy EJ; Singh RN
    Mol Cell Biol; 2006 Feb; 26(4):1333-46. PubMed ID: 16449646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
    Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7.
    Staropoli JF; Li H; Chun SJ; Allaire N; Cullen P; Thai A; Fleet CM; Hua Y; Bennett CF; Krainer AR; Kerr D; McCampbell A; Rigo F; Carulli JP
    Genomics; 2015 Apr; 105(4):220-8. PubMed ID: 25645699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of trans-acting elements that promote exon 7 skipping of SMN2 in SMN2-GFP stable cell line.
    Cho S; Moon H; Yang X; Zhou J; Kim HR; Shin MG; Loh TJ; Zheng X; Shen H
    Biochem Biophys Res Commun; 2012 Jul; 423(3):531-5. PubMed ID: 22683329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.